Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies
Regulatory Clearances Support Glaukos' Plans to Advance and Accelerate its Interventional Glaucoma Initiatives Globally
Marks the Company's First Regulatory Clearances Under the New EU Regulatory Framework
ALISO VIEJO, Calif., June 25, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite®, along with several of its other leading micro-invasive glaucoma surgery (MIGS) technologies, including iStent inject® W. Glaukos' iStent® trabecular micro-bypass stenting platform primarily involves the insertion of a micro-scale surgical devices designed to reduce intraocular pressure by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma.
"We are pleased to receive these important regulatory clearances for our leading trabecular micro-bypass stenting devices, marking our company's first approvals under the new EU regulatory framework," said Thomas Burns, Glaukos chairman and chief executive officer. "These important milestones will not only help us maintain and grow our presence in Europe but also advance and accelerate our broader Interventional Glaucoma initiatives globally. We are eager to commence commercial launch activities for these novel MIGS therapies over the coming months."
These certifications affirm that iStent infinite and iStent inject W meet the stringent requirements of the EU MDR – a new, robust framework established to ensure high standards of quality, safety and effectiveness for medical devices marketed in the EU.
Glaukos is proud to be the corporate pioneer and global market leader in MIGS, with its family of iStent technologies supported by nearly 400 peer-reviewed publications, 20 plus years of clinical and commercial experience and more than one million iStent devices implanted worldwide since its inception. The company believes it offers the industry's most comprehensive offering of minimally-invasive, tissue-sparing glaucoma solutions, supporting its goal to provide a full range of options to fit surgeons' individual glaucoma treatment algorithms that offer the most favorable short- and long-term benefit-to-risk calculus at every stage of disease progression, from ocular hypertension through refractory disease, and in both combo-cataract and standalone procedures.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
About iStent infinite® Trabecular Micro-Bypass System (U.S.)
Indication for Use: The iStent infinite Trabecular Micro-Bypass System Model iS3 is an implantable device intended to reduce the intraocular pressure (IOP) of the eye. It is indicated for use in adult patients with primary open-angle glaucoma in whom previous medical and surgical treatment has failed.
Contraindications: The iStent infinite is contraindicated in eyes with angle-closure glaucoma where the angle has not been surgically opened, acute traumatic, malignant, active uveitic, or active neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.
Warnings: Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization that could lead to improper placement of the stent and pose a hazard.
MRI Information: The iStent infinite is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.
Precautions: The surgeon should monitor the patient postoperatively for proper maintenance of IOP. Three out of 61 participants (4.9%) in the pivotal clinical trial were phakic. Therefore, there is insufficient evidence to determine whether the clinical performance of the device may be different in those who are phakic versus in those who are pseudophakic.
Adverse Events: The most common postoperative adverse events reported in the iStent infinite pivotal trial included IOP increase ≥ 10 mmHg vs. baseline IOP (8.2%), loss of BSCVA ≥ 2 lines (11.5%), ocular surface disease (11.5%), perioperative inflammation (6.6%) and visual field loss ≥ 2.5 dB (6.6%).
Caution: Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.
For more information, visit www.glaukos.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250625924718/en/
Contacts
Chris LewisVice President, Investor Relations & Corporate Affairs(949) 481-0510clewis@glaukos.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
32 minutes ago
- Business Insider
TD Cowen Keeps Their Hold Rating on General Mills (GIS)
In a report released today, Robert Moskow from TD Cowen maintained a Hold rating on General Mills (GIS – Research Report), with a price target of $48.00. The company's shares closed today at $50.68. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Moskow is a 3-star analyst with an average return of 2.2% and a 47.57% success rate. Moskow covers the Consumer Defensive sector, focusing on stocks such as Campbell Soup, Conagra Brands, and General Mills. In addition to TD Cowen, General Mills also received a Hold from Barclays's Andrew Lazar in a report issued today. However, yesterday, Morgan Stanley maintained a Sell rating on General Mills (NYSE: GIS). The company has a one-year high of $75.90 and a one-year low of $52.39. Currently, General Mills has an average volume of 4.94M. Based on the recent corporate insider activity of 83 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GIS in relation to earlier this year. Last month, Pankaj MN Sharma, the Segment President of GIS sold 3,643.00 shares for a total of $197,159.16.
Yahoo
38 minutes ago
- Yahoo
EU to canvass leaders at summit on resolving US tariff conflict
By Philip Blenkinsop and Jan Strupczewski BRUSSELS (Reuters) -European Union leaders are to tell the European Commission on Thursday if they want a quick trade deal with the United States at the cost of Washington getting better terms, or to escalate the fight in hope of something better. A quick deal seems to be the preferred option for most, officials and diplomats said, as the EU can then seek to address the unfavourable bias with some rebalancing measures of its own. The Commission, which negotiates trade agreements on behalf of the EU, will ask leaders of the EU's 27 members meeting in Brussels how they want to respond to President Donald Trump's July 9 deadline for a deal, now less than two weeks away. The bloc has said it is striving for a mutually beneficial agreement, but as Washington looks set to stick to its 10% across-the board tariffs on most EU goods and threatening higher rates with prolonged talks, EU diplomats said a growing number of EU countries were now favouring a quick resolution. "It is ...in everyone's interest that the trade conflict with the United States does not escalate further," German Chancellor Friedrich Merz said on Tuesday in parliament. "I know that the European Commission is negotiating with great caution in this regard, and it has our full support. I hope that we will reach a solution with the United States by the beginning of July," Merz said. The bloc is already facing U.S. import tariffs of 50% on its steel and aluminium, 25% for cars and car parts, along with a 10% tariff on most other EU goods, which Trump has threatened could rise to 50% without an agreement. The United States' only completed trade deal to date is with Britain, with the broad 10% tariff still in place. U.S. officials say it will not go lower for any trading partner. Some 23 of the leaders will come to Brussels straight from the NATO summit in the Hague. Few will want to follow accord there with an economic war. "There is a group of EU countries that want to protect companies by seemingly accepting something they have gotten used to – a 10% baseline," one EU diplomat said. REBALANCING MEASURES One question EU leaders face is whether it should respond with its own measures to such a baseline tariff. "We are also prepared for that with a range of options," Merz said. The European Union has agreed, but not imposed, tariffs on 21 billion euros of U.S. goods and is debating a further package of tariffs on up to 95 billion euros of U.S. imports. Some EU countries favour watering it down. "The Commission has rightly said that some member states are nibbling away too much, which would weaken these rebalancing measures," one EU diplomat. Among the EU rebalancing options is a tax on digital advertising, which would hit U.S. giants like Alphabet Inc's Google, Meta , Apple , X or Microsoft and eat into the trade surplus in services the U.S. has with the EU. The bloc has a trade surplus with the U.S. in goods. The Commission has proposed an EU-US deal to cut respective tariffs on industrial goods to zero, along with potential further EU purchases of liquefied natural gas and soybeans. Washington has shown little obvious interest, preferring to highlight items it considers as barriers, such as EU value-added tax, environmental standards and rules on online platforms, on which the EU does not want to move. On the sidelines of the summit, EU leaders will also seek to allay the concerns of Slovakia and Hungary over ending their access to Russian gas as foreseen by the EU's plan to phase out all Russian gas imports by the end of 2027. EU diplomats said EU leaders' assurances over gas should allow the two countries to back the EU's 18th package of sanctions against Russia, which they are now blocking. The sanctions could be adopted by EU governments on Friday. But the EU might have to drop from the package its proposal to lower the price cap on Russian seaborne oil to $45 per barrel from the current $60, because the measure has failed to win the support of the U.S. and EU countries with big oil shipping industries - Greece, Malta and Cyprus -- are also against it. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
an hour ago
EU leaders meet to discuss tougher Russia sanctions, US tariffs and Middle East
BRUSSELS -- The heads of the European Union's 27 member nations will meet Thursday in Brussels to discuss tougher sanctions on Russia, ways to prevent painful new U.S. tariffs, and how to make their voices heard in the Middle East conflicts. Most of the leaders will arrive from a brief but intense NATO summit where they pledged a big boost in defense spending, and papered over some of their differences with U.S. President Donald Trump. Ukrainian President Volodymyr Zelenskyy will join the EU summit by videoconference, after meeting Trump on Wednesday. U.S.-led NATO downgraded Ukraine from a top priority to a side player this week, but Russia's war in Ukraine remains of paramount concern for the EU. Members will be discussing an 18th round of sanctions against Russia and whether to maintain a price cap on Russian oil, measures that some nations oppose because it could raise energy prices. Meanwhile, Trump's threatened tariffs are weighing on the EU, which negotiates trade deals on behalf of all 27 member countries. He lashed out at Spain on Wednesday for not spending more on defense and suggested yet more tariffs. France's president called Trump to task for starting a trade war with longtime allies. European leaders are also concerned about fallout from the wars in the Middle East, and the EU is pushing to revive diplomatic negotiations with Iran over its nuclear program. EU members have internal disagreements to overcome. They are divided over what to do about European policy toward Israel because of its conduct in Gaza. And left-leaning parties are attacking European Commissioner Ursula von Der Leyen's pivot away from the EU's climate leadership in favor of military investment. Defense and security are likely to top the agenda. The summit will end with a statement of conclusions that will set the agenda for the bloc for the next four months and can be seen as a bellwether for political sentiment in Europe on major regional and global issues.
